Why did NOX.AX stock spike pre-market today?

NOX.AX stock spiked due to heightened trading ahead of clinical readouts and an upcoming earnings announcement on 2026-02-23, combined with a volume surge to **1,390,683** shares that amplified short-term momentum.

What is Meyka AI's forecast for NOX.AX stock?

Meyka AI's forecast model projects a yearly price of **A$0.09** for NOX.AX stock, implying an upside of **8.67%** versus the current A$0.08. Forecasts are model-based projections and not guarantees.

How does NOX.AX stock rate on valuation and risk?

NOX.AX stock shows high valuation metrics: price-to-book **29.63** and price-to-sales **7.25**, EPS **-0.02**, and debt-to-equity **3.59**, signalling valuation and leverage risks tied to binary clinical outcomes.

What trading strategy suits NOX.AX stock in pre-market top gains?

For NOX.AX stock, short-term traders can use momentum entries with stops below **A$0.07** and scaled exposure; longer-term investors should wait for earnings or clinical clarity before increasing allocation.

AU Stocks

NOX.AX Noxopharm (ASX) up 35.59% pre-market 12 Feb 2026: catalyst and outlook

ByDanny Kontos February 11, 2026February 11, 2026

NOX.AX stock jumped 35.59% pre-market to A$0.08 on 12 Feb 2026 after heavy volume of 1,390,683 shares. The move makes Noxopharm Limited (NOX.AX) one of the ASX top gainers this pre-market session and follows renewed interest in its oncology programs. Traders are pricing short-term momentum while analysts flag mixed fundamentals: market cap A$20,456,657.00, EPS -0.02, and PE -3.50.